RxDoctor Payments Data

Megan Hambel

Family · Melbourne, FLNPI 1992228555

Payments from drug & device makers

$685in general payments, 2019–2025

Across 26 payments — averaging $26.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$219
  • Cvrx, Inc.$161
  • Novartis$118
  • Impulse Dynamics (USA) Inc.$48
  • Boehringer Ingelheim$31
  • Biotronik Inc.$30
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$685 in reported general payments places this provider in the 60th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$119,562
Medicare patients
538
Services billed
1,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$218,653
EntrestoSacubitril/Valsartan105$119,441
JardianceEmpagliflozin43$48,807
MultaqDronedarone Hcl25$46,142
Dabigatran EtexilateDabigatran Etexilate Mesylate83$30,612
XareltoRivaroxaban19$22,511
Ranolazine ErRanolazine25$5,672
Metoprolol Succinate198$4,550
Rosuvastatin Calcium180$3,508
Losartan Potassium182$2,916
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$2,679
Valsartan62$2,396
Midodrine Hcl30$1,991
Amlodipine Besylate159$1,681
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide63$1,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$118$119,441105 claims
Boehringer IngelheimJardiance$31$48,80743 claims
Johnson & JohnsonXarelto$21$22,51119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 14,618 family providers in Florida.

Other family in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →